144 related articles for article (PubMed ID: 20073409)
1. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen.
Couto JE; Webster L; Romney MC; Leider HL; Linden A
J Opioid Manag; 2009; 5(6):359-64. PubMed ID: 20073409
[TBL] [Abstract][Full Text] [Related]
2. Use of an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen.
Couto JE; Webster L; Romney MC; Leider HL; Linden A
J Clin Pharm Ther; 2011 Apr; 36(2):200-7. PubMed ID: 21166833
[TBL] [Abstract][Full Text] [Related]
3. Does therapeutic use of tapentadol cause false-positive urine screens for methadone or opiates?
Mullins ME; Hock K; Scott MG
Clin Toxicol (Phila); 2015 Jun; 53(5):493-4. PubMed ID: 25951899
[No Abstract] [Full Text] [Related]
4. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
[TBL] [Abstract][Full Text] [Related]
5. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
[TBL] [Abstract][Full Text] [Related]
6. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
7. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
[No Abstract] [Full Text] [Related]
8. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
Luo Z; Miao J; Shu S; Wang Y; Zhu X; Hu C; Shen Y
Clin Drug Investig; 2020 Feb; 40(2):139-148. PubMed ID: 31679120
[TBL] [Abstract][Full Text] [Related]
10. A Novel Oral Fluid Assay (LC-QTOF-MS) for the Detection of Fentanyl and Clandestine Opioids in Oral Fluid After Reported Heroin Overdose.
Griswold MK; Chai PR; Krotulski AJ; Friscia M; Chapman BP; Varma N; Boyer EW; Logan BK; Babu KM
J Med Toxicol; 2017 Dec; 13(4):287-292. PubMed ID: 28971325
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
[TBL] [Abstract][Full Text] [Related]
13. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
McCarberg BH
Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
[TBL] [Abstract][Full Text] [Related]
14. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
[TBL] [Abstract][Full Text] [Related]
15. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites.
Heltsley R; Zichterman A; Black DL; Cawthon B; Robert T; Moser F; Caplan YH; Cone EJ
J Anal Toxicol; 2010; 34(1):32-8. PubMed ID: 20109300
[TBL] [Abstract][Full Text] [Related]
16. The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS/MS gold standard.
Abou El Hassan M; Colantonio D; Likhodii S; Nassar BA
Clin Biochem; 2021 Jul; 93():99-103. PubMed ID: 33844982
[TBL] [Abstract][Full Text] [Related]
17. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration.
Cone EJ; Heltsley R; Black DL; Mitchell JM; Lodico CP; Flegel RR
J Anal Toxicol; 2013 Jun; 37(5):255-64. PubMed ID: 23609023
[TBL] [Abstract][Full Text] [Related]
18. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
19. Suitability of the DRI Hydrocodone/Hydromorphone Immunoassay in the Clinical Environment at a Lower Cutoff: Validation With LC-MS/MS Analysis.
Dixon RB; Dasgupta A
Ther Drug Monit; 2016 Dec; 38(6):787-790. PubMed ID: 27764026
[TBL] [Abstract][Full Text] [Related]
20. Development of a Quantitative LC-MS-MS Assay for Codeine, Morphine, 6-Acetylmorphine, Hydrocodone, Hydromorphone, Oxycodone and Oxymorphone in Neat Oral Fluid.
Grabenauer M; Moore KN; Bynum ND; White RM; Mitchell JM; Hayes ED; Flegel R
J Anal Toxicol; 2018 Jul; 42(6):392-399. PubMed ID: 29554298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
